1292. Viruses Associated with Acute Respiratory Illnesses (ARI) in Hospitalized Pediatric Patients 5-17 Years of Age in the US
Session: Poster Abstract Session: Clinical Infectious Diseases: Respiratory Infections
Friday, October 28, 2016
Room: Poster Hall
Posters
  • Sahni IDWeek 1292.pdf (119.9 kB)
  • Background: Knowledge about the etiology of ARI in hospitalized children ≥5 years of age and adolescents is limited.

    Methods: Children 5-17 years of age hospitalized with ARI were enrolled through active surveillance at 6 pediatric hospitals in the New Vaccine Surveillance Network between 10/1/2015 and 3/31/2016. Combined mid-turbinate and throat swabs were collected and tested for adenovirus, influenza, human metapneumovirus (HMPV), parainfluenza viruses (PIV), rhinovirus/enterovirus (HRV), and respiratory syncytial virus (RSV) using molecular techniques at each site.

    Results: Among 479 children, viruses were detected in 249 (52%) in preliminary analysis. Median age of children was 8.3 years; 267 (56%) were male, 236 (49%) were white, and 329 (69%) were publicly insured. A single virus was detected in 234 (49%) samples; ≥2 viruses were identified in 15 (3%) samples (Table). HRV was most commonly detected (n=152, 32%), followed by RSV (n=40, 8%), and influenza (n=27, 6%).

    Conclusion: Current data using molecular diagnostics to identify viruses in children hospitalized with ARI could improve prevention, evaluation, and treatment by healthcare professionals and inform future vaccine policy.

     


    Table. Viruses detected

     

    Adenovirus

    Influenza

    HMPV

    PIV

    HRV

    RSV

    Co-Infections

     

    n=12

    (3%)

    n=27

    (6%)

    n=21

    (4%)

    n=13

    (3%)

    n=152

    (32%)

    n=40

    (8%)

    n=15

    (3%)

    Male, n (%)

    9 (75)

    12 (44)

    13 (62)

    6 (46)

    96 (63)

    21 (53)

    10 (67)

    Age (year)
    Median, range

    7.4

    5.2-13.3

    9.5

    5.5-16.8

    7.6

    5.6-16.0

    6.5

    5.6-15.7

    7.8

    5.0-17.7

    7.2

    5.0-16.6

    6.4

    5.1-11.5

    Race, n (%)

     

     

     

     

     

     

     

    White

    8 (67)

    13 (48)

    13 (62)

    7 (54)

    65 (43)

    23 (58)

    7 (47)

    Black

    4 (33)

    7 (26)

    5 (24)

    2 (15)

    55 (36)

    11 (28)

    7 (47)

    Other

    --

    7 (26)

    3 (14)

    4 (31)

    32 (21)

    6 (14)

    1 (6)

    Ethnicity, n (%)

     

     

     

     

     

     

     

    Hispanic

    3 (25)

    8 (30)

    5 (24)

    5 (38)

    35 (23)

    14 (35)

    2 (13)

    Non-Hispanic

    9 (75)

    19 (70)

    16 (76)

    8 (62)

    115 (76)

    26 (65)

    13 (87)

    Insurance, n (%)

     

     

     

     

     

     

     

    Public

    6 (50)

    21 (78)

    15 (71)

    8 (62)

    110 (72)

    24 (60)

    12 (80)

    Private

    6 (50)

    5 (19)

    6 (24)

    5 (38)

    37 (24)

    16 (40)

    3 (20)

    None

    --

    1 (4)

    --

    --

    5 (3)

    --

    --

     

     

    Leila C. Sahni, MPH1, Pedro Piedra, MD2, Flor Munoz, MD3, Julie Boom, MD4,5, Parvin H. Azimi, MD6, Rangaraj Selvarangan, PhD7, Natasha Halasa, MD, MPH, FPIDS8, Janet Englund, MD, FIDSA9, Geoffrey Weinberg, MD, FIDSA, FPIDS10, Daniel Payne, PhD, MSPH11, Daniella Figueroa-Downing, MPH12, Alicia M. Fry, MD, MPH13, Angela P. Campbell, MD, MPH, FPIDS13, Susan Gerber, MD14 and Brian Rha, MD, MSPH15, (1)Immunization Project, Texas Children's Hospital, houston, TX, (2)Baylor College of Medicine, Houston, TX, (3)Pediatric Infectious Diseases, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, (4)Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA, Houston, TX, (5)Immunization Project, Texas Children’s Hospital, TX, USA, Houston, TX, (6)Children's Hospital, Oakland, CA, (7)Children's Mercy Hospital and Clinics, Kansas City, MO, (8)Vanderbilt University Medical Center, Nashville, TN, (9)Infectious Disease/Cctr, Seattle Children's Hospital, Seattle, WA, (10)Pediatrics, Univ. of Rochester Sch. of Med. and Dent., Rochester, NY, (11)Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, (12)Centers for Disease Control and Prevention, Atlanta, GA, (13)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, (14)Division of Viral Diseases/Epidemiology Branch, Centers for Disease Control and Prevention, Atlanta, GA, (15)Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA

    Disclosures:

    L. C. Sahni, None

    P. Piedra, None

    F. Munoz, NIH, CDC, Novavax, Alios, Biocryst, Ansun, Regeneron, Chimerix: Investigator , Research support
    CDC, Novavax, Pfizer, GSK: Scientific Advisor , Consulting fee

    J. Boom, None

    P. H. Azimi, None

    R. Selvarangan, None

    N. Halasa, Pfizer: Grant Investigator , Research grant
    Biocryst: Grant Investigator , Research support
    AstraZeneca: Grant Investigator , Research support
    Baxter: Grant Investigator , Research grant

    J. Englund, Pfizer: Consultant and Investigator , Research support and Speaker honorarium
    Gilead: Consultant and Investigator , Consulting fee and Research support
    GlaxoSmithKline: Investigator and Member Data Safety Monitoring BOard , Hourly payment for DSMB work and Research support
    Alios: Investigator , Research support
    Roche: Investigator , Research support

    G. Weinberg, None

    D. Payne, None

    D. Figueroa-Downing, None

    A. M. Fry, None

    A. P. Campbell, None

    S. Gerber, None

    B. Rha, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.